BIOMARIN PHARMACEUTICAL INC

BioMarin Pharmaceutical Inc. is a leading global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company operates in the biopharmaceutical industry, specifically targeting rare genetic diseases with small patient populations. The filing describes the industry as rapidly evolving and highly competitive, with many public and private companies, universities, and non-profit research organizations pursuing programs for the same indications. BioMarin's strategy involves pursuing category-defining medicines through a distinctive approach to drug discovery and development, leveraging internal research programs, partnerships, and acquisitions of external assets.

BioMarin's competitive positioning is built on a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. The filing names several primary competitors, including Abbisko Therapeutics Co Ltd., Ascendis Pharma A/S, QED Therapeutics, Inc. (a subsidiary of BridgeBio Pharma, Inc.), Ribomic Inc., Tyra Biosciences Inc., ArmaGen, Inc., JCR Pharmaceuticals Co., Ltd., Orchard Therapeutics Plc, RegenxBio Inc., Inventiva S.A., Paradigm Biopharmaceuticals Limited, Lexeo Therapeutics, Inc., the Roche Group, PTC Therapeutics, Inc., Agios Pharmaceuticals Inc., Jnana Therapeutics Inc. (a subsidiary of Otsuka Pharmaceutical Co., Ltd.), Maze Therapeutics, NGGT Inc., Relief Therapeutics, SOM Innovation Biotech, S.A., Scohia Pharma Inc., Sarepta Therapeutics, Inc., Catalyst Pharmaceuticals, Inc., Santhera Pharmaceuticals Holdings AG, Italfarmaco S.p.A., Dyne Therapeutics, Inc., and Solid Biosciences, Inc. The company's competitive advantages include its intellectual property portfolio, with active patents and patent applications for products like BRINEURA, PALYNZIQ, VIMIZIM, and VOXZOGO, as well as regulatory exclusivity in the U.S. and EU. For example, VOXZOGO has U.S. orphan drug exclusivity for children of five years of age and older expiring in 2028 and for children of less than five years of age expiring in 2030 ¹. The filing notes that other than PALYNZIQ and KUVAN, its products have no direct approved competition currently on the market in the U.S. or the EU, though other companies are in development phases.

BioMarin generates revenue primarily through the sale of its commercial therapies, which are approved for marketing in the U.S., EU, and other international markets. The company's revenue model is product-based, with net product revenues constituting the vast majority of total revenues. For ALDURAZYME, revenue is recognized based on a payment ranging from 39.5% to 50% on worldwide net sales by Sanofi, depending on sales volume ². The company also earns royalty and other revenues. Customer segments include a limited number of specialty pharmacies, hospitals, non-U.S. government agencies, and authorized distributors. PALYNZIQ is distributed in the U.S. through a limited number of certified specialty pharmacies under a Risk Evaluation and Mitigation Strategy (REMS) program. Sanofi is the sole customer for ALDURAZYME. The company's commercial organization is structured around two business units: Skeletal Conditions (VOXZOGO) and Enzyme Therapies.

BioMarin's commercial product portfolio consists of eight therapies. VOXZOGO (vosoritide) is a once-daily injection for achondroplasia, approved in the U.S., Japan, EU, and other markets, with 2025 net product revenues of $926.9 million ³. Enzyme Therapies include VIMIZIM (elosulfase alpha) for MPS IVA with revenues of $792.1 million ⁴, NAGLAZYME (galsulfase) for MPS VI with revenues of $485.4 million ⁵, PALYNZIQ (pegvaliase-pqpz) for PKU with revenues of $433.3 million ⁶, ALDURAZYME (laronidase) for MPS I with revenues of $208.5 million ⁷, BRINEURA (cerliponase alfa) for CLN2 with revenues of $186.4 million ⁸, KUVAN (sapropterin dihydrochloride) for PKU with revenues of $99.6 million ⁹, and ROCTAVIAN (valoctocogene roxaparvovec) for severe Hemophilia A with revenues of $35.6 million ¹⁰. The company also has a clinical and preclinical pipeline, including BMN 333, a longer-acting CNP for growth disorders, BMN 351, a next-generation oligonucleotide for Duchenne Muscular Dystrophy (DMD), and BMN 401 (formerly INZ-701), an enzyme replacement therapy for ENPP1 deficiency acquired through the Inozyme acquisition.

In 2025, BioMarin achieved total revenues of $3.2 billion ¹¹, including a significant contribution from the ongoing expansion of VOXZOGO. The company continued to grow its commercial business and advance its product candidate pipeline. In December 2025, BioMarin entered into a definitive agreement to acquire Amicus Therapeutics, Inc. for $14.50 per share in an all-cash transaction for a total consideration of approximately $4.8 billion ¹². The transaction is expected to close in the second quarter of 2026. In connection with this, the company entered into a debt financing commitment for up to approximately $3.7 billion ¹³ in the form of a 364-day senior secured bridge loan facility. In February 2026, BioMarin issued $850.0 million ¹⁴ in aggregate principal amount of 5.5% senior unsecured notes due 2034. In October 2025, the company announced plans to divest ROCTAVIAN, and in December 2025, committed to voluntarily withdraw it from the market, recording approximately $240.0 million ¹⁵ of restructuring charges comprised of an inventory write-off, impairment of long-lived assets, severance, and other costs. In July 2025, BioMarin completed the acquisition of Inozyme Pharma, Inc. to strengthen its enzyme therapies portfolio with BMN 401.

Total revenues for 2025 were $3,221.3 million ¹⁶, compared to $2,853.9 million ¹⁷ in 2024 and $2,419.2 million ¹⁸ in 2023. Net income for 2025 was $348.9 million ¹⁹, compared to $426.9 million ²⁰ in 2024 and $167.6 million ²¹ in 2023. Diluted earnings per share were $1.80 ²² in 2025, $2.21 ²³ in 2024, and $0.87 ²⁴ in 2023. The increase in total revenues in 2025 was primarily driven by higher sales volume of VOXZOGO, PALYNZIQ, VIMIZIM, ALDURAZYME, and BRINEURA, partially offset by lower KUVAN revenues due to generic competition. Gross margin decreased to 77.7% ²⁵ in 2025 from 79.7% ²⁶ in 2024, primarily due to the ROCTAVIAN inventory write-off. Net cash provided by operating activities was $828.0 million ²⁷ in 2025, compared to $572.8 million ²⁸ in 2024.

It states that the company believes the combination of internal research programs, partnerships, and acquisitions will allow it to continue to develop and commercialize innovative therapies. The company also notes that it periodically conducts strategic portfolio assessments and that certain programs that do not meet its threshold for further development could be discontinued.

A major growth vector is the continued expansion of VOXZOGO for the treatment of achondroplasia and the advancement of the CANOPY clinical program for conditions beyond achondroplasia, including hypochondroplasia, idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency. The filing states that VOXZOGO addresses larger patient populations than most of the company's other products. In 2025, the company continued to advance development across the CANOPY program, including a pivotal Phase 3 study in hypochondroplasia and Phase 2 studies in the other indications. Another growth vector is the expansion of the pipeline through external innovation, specifically the pending acquisition of Amicus Therapeutics, which is expected to strengthen the commercial portfolio by adding two new therapies for Fabry disease and late-onset Pompe disease. The acquisition of Inozyme Pharma in July 2025 added BMN 401, a late-stage enzyme replacement therapy for ENPP1 deficiency.However, it notes that the company's corporate strategy includes cost transformation. The gross margin decreased to 77.7% ²⁹ in 2025 from 79.7% ³⁰ in 2024, primarily due to the $119.2 million ³¹ write-off of ROCTAVIAN inventory. The company expects interest expense to increase over the next 12 months due to financing related to the pending Amicus acquisition, including the 2034 Notes issued in February 2026.

The filing describes the company's manufacturing operations, including facilities in Novato, California and Shanbally, Cork, Ireland. The Novato facility manufactures API for ALDURAZYME, NAGLAZYME, PALYNZIQ, and VOXZOGO. The Shanbally facility manufactures API for BRINEURA and VIMIZIM and has installed aseptic filling and drug product packaging capabilities, which received EU approval in 2024. The company contracts with third parties for the manufacture of PALYNZIQ and KUVAN API and for most drug product manufacturing. The company expects the volume mix to change as drug product filing operations initiate and expand at the Shanbally site. The company also notes that it is implementing a new global enterprise resource planning (ERP) system, which began deployment in January 2025 and is scheduled to occur in phases through 2026.

The company expects to continue to spend substantial amounts of capital for operations for the foreseeable future. Research and development expense was $921.9 million ³² in 2025. Capital expenditures for property, plant, and equipment were $103.0 million ³³ in 2025. The company has a $600.0 million ³⁴ unsecured revolving credit facility, with no amounts outstanding as of December 31, 2025. In February 2026, the company issued $850.0 million ³⁵ in aggregate principal amount of 5.5% senior unsecured notes due 2034. The company does not anticipate paying cash dividends in the foreseeable future. The filing does not mention a share repurchase authorization.

The filing identifies several headwinds and constraints. The company faces intense competition from other pharmaceutical companies, some with more extensive resources. Generic versions of KUVAN are available in several countries, including multiple generic versions in the U.S. and the EU, which has adversely affected and will continue to adversely affect revenues from KUVAN. The company also faces risks related to obtaining and maintaining adequate coverage and reimbursement from third-party payers, which is particularly challenging due to the high per-patient prices of its products. Government price controls and healthcare reform, such as the Inflation Reduction Act, could restrict pricing and adversely affect revenues. The company's international operations expose it to currency risks, with approximately 49% of net product sales denominated in foreign currencies in 2025. The company also faces risks related to supply interruptions, manufacturing complexities, and the need to comply with extensive ongoing regulatory requirements.

The most material risks specific to BioMarin include its dependence on a small number of products for the majority of its revenue, with VOXZOGO and VIMIZIM alone accounting for over $1.7 billion in combined 2025 net product revenues. The company faces significant competition from generic versions of KUVAN, which are available in several countries including multiple generic versions in the U.S. and the EU, and this has adversely affected and will continue to adversely affect revenues from KUVAN. The pending acquisition of Amicus Therapeutics for approximately $4.8 billion ³⁶ introduces substantial integration risk, including the potential failure to realize anticipated benefits, the incurrence of material expenses, and the assumption of significant debt, with the company planning to finance the transaction through a combination of cash on hand and approximately $3.7 billion ³⁷ of non-convertible debt financing. The company's international operations expose it to currency risk, with approximately 49% of net product sales denominated in foreign currencies in 2025, and a hypothetical 10% adverse movement in foreign currency exchange rates would have resulted in a reduction in the value of open forward contracts by approximately $152.9 million ³⁸ as of December 31, 2025. Finally, the company's success depends on its ability to obtain and maintain adequate coverage and reimbursement from third-party payers for its high-priced therapies, and government price controls or healthcare reform, such as the Inflation Reduction Act, could restrict pricing and adversely affect revenues.

Management's message emphasizes the company's focus on innovation, growth, and value commitment as part of its corporate strategy announced in 2024. Key themes include the continued expansion of VOXZOGO, the advancement of the pipeline through internal programs and external acquisitions, and a commitment to cost transformation. The filing states that in 2025, the company achieved $3.2 billion in total revenues ³⁹, including a significant contribution from the ongoing expansion of VOXZOGO, and continued to grow its commercial business and advance its product candidate pipeline. Management believes that the combination of internal research programs, partnerships, and acquisitions of external assets will allow the company to continue to develop and commercialize innovative therapies. The strategic priorities emphasized for the period ahead include completing the pending acquisition of Amicus Therapeutics, which is expected to close in the second quarter of 2026, and continuing to advance the CANOPY clinical program for VOXZOGO in indications beyond achondroplasia.